PCM
ELEV

Prelude Capital Management’s Elevation Oncology ELEV Stock Holding History

Prelude Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,240
Closed -$7.34K – 1292
2024
Q3 		$7.34K Sell
12,240
-79,754
-87% -$118K ﹤0.01% 1237
2024
Q2 		$248K Sell
91,994
-8,308
-8% -$31.3K 0.02% 888
2024
Q1 		$515K Buy
+100,302
New +$325K 0.03% 622

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's ELEV Position: Q4 2024 in Review

Prelude Capital Management sold out of Elevation Oncology (ELEV) in Q4 2024, closing a stake of 12,240 shares — an estimated $7.34K sold.

Prelude Capital Management first reported a position in ELEV in Q1 2024 and held it in 3 quarters. The position peaked at $515K in Q1 2024. 71 funds tracked by Wall St. Rank hold ELEV as of Q4 2024.

  • Prelude Capital Management reported no remaining Elevation Oncology position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 12,240 Elevation Oncology shares in Q4 2024, an estimated $7.34K.
  • Prelude Capital Management first reported a position in Elevation Oncology in Q1 2024 and held it in 3 quarters.
  • Prelude Capital Management's Elevation Oncology position peaked at $515K in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.